Merck & Company (MRK)

$129.56 +4.19 (3.34%)
Market Cap 319.99B
Revenue (ttm) 65.01B
Net Income (ttm) 18.25B
EPS (ttm) N/A
PE Ratio 22.92
Forward PE 24.16
Profit Margin 28.08%
Debt to Equity Ratio 1.02
Volume 7,833,900
Avg Vol 10,557,378
Day's Range N/A - N/A
Shares Out 2.47B
Stochastic %K 96%
Beta 0.19
Analysts Strong Sell
Price Target $132.15

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
harmongreg
harmongreg Jul. 4 at 5:27 PM
Dragonfly Capital - 5 Trade Ideas for Monday: American Express, eBay, Merck, Microsoft and Sherwin-Williams $AXP $EBAY $MRK $MSFT $SHW https://dragonflycap.com/5-trade-ideas-for-monday-american-express-ebay-merck-microsoft-and-sherwin-williams/
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
PamelaJorge270
PamelaJorge270 Jul. 3 at 9:13 PM
$MRK halts its Phase 2 Alzheimer’s trial after weak efficacy readout. This looks like another reminder that CNS is a tough endpoint game. Short-term sentiment likely pressured, and the market may keep discounting near-term pipeline upside until clearer data shows up.
0 · Reply
taxplanr
taxplanr Jul. 3 at 3:43 PM
$MRK Keytruda https://www.instagram.com/reel/DaJjsbQic0l/?igsh=MTBoNWV6cGRlN3Q4OQ==
0 · Reply
ETAlpha
ETAlpha Jul. 2 at 9:39 PM
$MRK $ABBV Annoying to watch ABBV and others rip this week while MRK dragged. Major underperformance, but sector rotation is real. Weekend prediction: MRK is heavily oversold on the daily. Expecting a gap up or a fast relief bounce early next week to catch up with big pharma. Watching closely.
0 · Reply
liamsniperalert
liamsniperalert Jul. 2 at 7:20 PM
$MRK 130 CALL 7/10 @ 1.40 🗻
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 2:23 PM
$BIIB $IGC $LLY $MRK $PFE $IGC the share price is climbing because buyers are positioning ahead of the Phase 2 CALMA data. Smart money often looks to get in before potential catalysts—not after them. If CALMA delivers positive results, today’s prices could look like a bargain. 🚀🧠 #IGC #Alzheimers #Biotech
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 2 at 2:15 PM
$CDXS $ARWR $MRK "As several experts pointed out, our manufacturing advancements to increase scale and reach larger patient populations will necessitate improvements in COGS and sustainability. Obviously, one of the ways to do this is to increase a drug’s durability/lower doses. We likely will start to see economies of scale work in our favor; a larger number of companies targeting stereopure molecules means lower costs of raw materials and manufacturing overall. As Jason Costigan, head of CMC for Corsera Health articulated, “We have to go where the puck is going, and I think that the puck is going toward stereopure products. I think it’s highly, highly likely that the regulatory expectation will be that you define a single diastereomer down the road,” Fleitz agreed with Costigan. “It’s not going to be next week; it’s not going to be next year. But that’s likely where we’re going.” https://www.advancingrna.com/doc/stay-stereocurious-what-the-future-holds-for-oligo-quality-0001
0 · Reply
Latest News on MRK
Merck terminates Phase 2 Alzheimer’s study

2026-07-01T18:35:17.000Z - 3 days ago

Merck terminates Phase 2 Alzheimer’s study

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Jul 1, 2026, 6:45 AM EDT - 3 days ago

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

Merck price target raised to $155 from $136 at Scotiabank

2026-06-30T14:15:11.000Z - 4 days ago

Merck price target raised to $155 from $136 at Scotiabank

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

2026-06-30T14:05:22.000Z - 4 days ago

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

ABBV

Merck price target raised to $141 from $130 at BofA

2026-06-30T12:05:18.000Z - 4 days ago

Merck price target raised to $141 from $130 at BofA

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 4 days ago

US House committee opens investigation into Merck, AbbVie China drug trials

ABBV

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Jun 29, 2026, 5:08 PM EDT - 4 days ago

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

Merck price target raised to $155 from $136 at Scotiabank

2026-06-29T18:35:14.000Z - 5 days ago

Merck price target raised to $155 from $136 at Scotiabank

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Jun 29, 2026, 6:45 AM EDT - 5 days ago

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

The Big 3: JPM, DHR, MRK

Jun 25, 2026, 1:00 PM EDT - 9 days ago

The Big 3: JPM, DHR, MRK

DHR JPM

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy

2026-06-25T10:50:37.000Z - 9 days ago

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy

GILD

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Jun 25, 2026, 6:45 AM EDT - 9 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

Merck says EC approves Keytruda plus Padcev combination

2026-06-24T10:50:33.000Z - 10 days ago

Merck says EC approves Keytruda plus Padcev combination

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Jun 24, 2026, 6:45 AM EDT - 10 days ago

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Merck initiated with an Outperform at CICC

2026-06-24T01:00:13.000Z - 10 days ago

Merck initiated with an Outperform at CICC

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Jun 23, 2026, 10:00 AM EDT - 11 days ago

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Merck's bowel disease drug meets main goal in late-stage trial

Jun 22, 2026, 7:16 AM EDT - 12 days ago

Merck's bowel disease drug meets main goal in late-stage trial

Merck announces ‘positive’ results from Phase 3 trial of tulisokibart

2026-06-22T10:47:10.000Z - 12 days ago

Merck announces ‘positive’ results from Phase 3 trial of tulisokibart

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Jun 22, 2026, 6:45 AM EDT - 12 days ago

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Merck says FDA approves additional indication for Capvaxive

2026-06-18T10:50:55.000Z - 16 days ago

Merck says FDA approves additional indication for Capvaxive

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Jun 18, 2026, 6:45 AM EDT - 16 days ago

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Jun 18, 2026, 6:45 AM EDT - 16 days ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Jun 17, 2026, 6:45 AM EDT - 17 days ago

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

Jun 16, 2026, 8:00 AM EDT - 18 days ago

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Jun 12, 2026, 4:10 PM EDT - 21 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 23 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Merck Animal Health to Acquire TARGAN

Jun 11, 2026, 6:45 AM EDT - 23 days ago

Merck Animal Health to Acquire TARGAN

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 11:20 AM EDT - 25 days ago

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 25 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY NVO PFE

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

Jun 9, 2026, 3:20 AM EDT - 25 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY PFE RDW UTHR XBI

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

Jun 8, 2026, 4:35 PM EDT - 25 days ago

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

GILD

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

Jun 8, 2026, 4:30 PM EDT - 25 days ago

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

GILD

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

Jun 8, 2026, 8:00 AM EDT - 26 days ago

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

Merck & Co. Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 10:30 AM EDT - 4 weeks ago

Merck & Co. Transcript: Jefferies Global Healthcare Conference 2026

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 6:45 AM EDT - 4 weeks ago

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Merck & Co. Transcript: Investor update

Jun 1, 2026, 7:00 PM EDT - 4 weeks ago

Merck & Co. Transcript: Investor update

Merck & Co. Press release: Investor update

Jun 1, 2026, 7:00 PM EDT - 4 weeks ago

Merck & Co. Press release: Investor update

Merck & Co. Slides: Investor update

Jun 1, 2026, 7:00 PM EDT - 4 weeks ago

Merck & Co. Slides: Investor update

Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Jun 1, 2026, 12:55 PM EDT - 4 weeks ago

Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

MRNA

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

May 29, 2026, 6:45 AM EDT - 5 weeks ago

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Merck to Participate in the Jefferies Global Healthcare Conference

May 28, 2026, 6:45 AM EDT - 5 weeks ago

Merck to Participate in the Jefferies Global Healthcare Conference

Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.

May 27, 2026, 2:23 PM EDT - 5 weeks ago

Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.

MA

Merck chicken bronchitis vaccine approved for use in China

May 27, 2026, 3:10 AM EDT - 5 weeks ago

Merck chicken bronchitis vaccine approved for use in China

Merck Announces Third-Quarter 2026 Dividend

May 26, 2026, 1:28 PM EDT - 5 weeks ago

Merck Announces Third-Quarter 2026 Dividend

Merck & Co. Transcript: AGM 2026

May 26, 2026, 9:00 AM EDT - 5 weeks ago

Merck & Co. Transcript: AGM 2026

Merck & Co. Slides: FY 2026

May 26, 2026, 9:00 AM EDT - 5 weeks ago

Merck & Co. Slides: FY 2026

Merck stock jumps as Keytruda combo trials boost cancer pipeline

May 22, 2026, 2:31 PM EDT - 6 weeks ago

Merck stock jumps as Keytruda combo trials boost cancer pipeline

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

May 22, 2026, 10:23 AM EDT - 6 weeks ago

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

May 22, 2026, 7:55 AM EDT - 6 weeks ago

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

May 21, 2026, 5:06 PM EDT - 6 weeks ago

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

Moderna, Merck cancer combo cuts melanoma spread risk at five years

May 21, 2026, 5:03 PM EDT - 6 weeks ago

Moderna, Merck cancer combo cuts melanoma spread risk at five years

MRNA

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

May 21, 2026, 8:00 AM EDT - 6 weeks ago

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims

May 20, 2026, 11:00 AM EDT - 6 weeks ago

National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims

Merck's endometrial cancer drug meets late-stage trial goals

May 18, 2026, 6:51 AM EDT - 6 weeks ago

Merck's endometrial cancer drug meets late-stage trial goals

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

May 18, 2026, 6:45 AM EDT - 6 weeks ago

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

May 12, 2026, 6:45 AM EDT - 7 weeks ago

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

May 7, 2026, 2:05 PM EDT - 2 months ago

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

May 6, 2026, 9:00 AM EDT - 2 months ago

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

CRM

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

May 5, 2026, 8:45 AM EDT - 2 months ago

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

TERN

Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

May 4, 2026, 4:56 PM EDT - 2 months ago

Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Merck & Co. Earnings Call Transcript: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Earnings Call Transcript: Q1 2026

Merck & Co. Earnings release: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Earnings release: Q1 2026

Merck & Co. Slides: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Slides: Q1 2026

Merck & Co. Quarterly report: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Quarterly report: Q1 2026

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

Apr 30, 2026, 8:05 AM EDT - 2 months ago

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

Merck Sales Rise on Continued Keytruda Growth

Apr 30, 2026, 6:51 AM EDT - 2 months ago

Merck Sales Rise on Continued Keytruda Growth

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Apr 30, 2026, 6:32 AM EDT - 2 months ago

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Merck posts quarterly loss due to Cidara charge, sales rise 5%

Apr 30, 2026, 6:31 AM EDT - 2 months ago

Merck posts quarterly loss due to Cidara charge, sales rise 5%

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Apr 30, 2026, 6:30 AM EDT - 2 months ago

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

Apr 28, 2026, 6:45 AM EDT - 2 months ago

Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

harmongreg
harmongreg Jul. 4 at 5:27 PM
Dragonfly Capital - 5 Trade Ideas for Monday: American Express, eBay, Merck, Microsoft and Sherwin-Williams $AXP $EBAY $MRK $MSFT $SHW https://dragonflycap.com/5-trade-ideas-for-monday-american-express-ebay-merck-microsoft-and-sherwin-williams/
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 1:44 PM
$IGC $IGC is building serious momentum. 🔥 Phase 2 CALMA is fully enrolled (146 patients), most participants have already completed the study, and the next big catalyst is the topline data readout. If results are positive, this could be a game-changing moment. Meanwhile, TGR-63 remains a promising Alzheimer’s pipeline asset, with management expected to accelerate updates after CALMA. Add in IGC’s expanding AI platform, insider alignment, and upcoming catalysts, and the setup keeps getting stronger. Eyes on CALMA. The biggest move could still be ahead. 🚀🧠💰 $IGC $LLY $BIIB $JNJ $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC Bullish: CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s serious skin in the game. Their restricted Rule 144 shares mean no immediate insider dumping pressure. Balance sheet is stronger, cash is preserved, and insiders look locked & loaded ahead of the Phase 2 CALMA trial results. If the data is positive, expect a lot more eyes on igc 👀🚀 Tags: $LLY $JNJ $PFE $MRK
1 · Reply
GordoHLYK13
GordoHLYK13 Jul. 4 at 8:13 AM
$IGC CEO and PFO just converted $1.15M of debt into equity at $0.27/share instead of taking cash. That’s real skin in the game. Those are restricted Rule 144 shares, so there’s no immediate insider dumping pressure. They cleaned up the balance sheet, preserved cash, and look locked & loaded ahead of the upcoming Phase 2 CALMA trial results. Insiders don’t increase their equity exposure by millions of shares unless they see potential upside—but clinical trial outcomes remain uncertain until the data is released. 🚀📈 https://www.getnews.info/story/2026/07/01/igc-pharma-nyse-igc-ceo-and-cfo-acquire-more-than-42-million-shares/ $LLY $JNJ $PFE $MRK
0 · Reply
PamelaJorge270
PamelaJorge270 Jul. 3 at 9:13 PM
$MRK halts its Phase 2 Alzheimer’s trial after weak efficacy readout. This looks like another reminder that CNS is a tough endpoint game. Short-term sentiment likely pressured, and the market may keep discounting near-term pipeline upside until clearer data shows up.
0 · Reply
taxplanr
taxplanr Jul. 3 at 3:43 PM
$MRK Keytruda https://www.instagram.com/reel/DaJjsbQic0l/?igsh=MTBoNWV6cGRlN3Q4OQ==
0 · Reply
ETAlpha
ETAlpha Jul. 2 at 9:39 PM
$MRK $ABBV Annoying to watch ABBV and others rip this week while MRK dragged. Major underperformance, but sector rotation is real. Weekend prediction: MRK is heavily oversold on the daily. Expecting a gap up or a fast relief bounce early next week to catch up with big pharma. Watching closely.
0 · Reply
liamsniperalert
liamsniperalert Jul. 2 at 7:20 PM
$MRK 130 CALL 7/10 @ 1.40 🗻
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 2:23 PM
$BIIB $IGC $LLY $MRK $PFE $IGC the share price is climbing because buyers are positioning ahead of the Phase 2 CALMA data. Smart money often looks to get in before potential catalysts—not after them. If CALMA delivers positive results, today’s prices could look like a bargain. 🚀🧠 #IGC #Alzheimers #Biotech
0 · Reply
Fingerlickengood
Fingerlickengood Jul. 2 at 2:15 PM
$CDXS $ARWR $MRK "As several experts pointed out, our manufacturing advancements to increase scale and reach larger patient populations will necessitate improvements in COGS and sustainability. Obviously, one of the ways to do this is to increase a drug’s durability/lower doses. We likely will start to see economies of scale work in our favor; a larger number of companies targeting stereopure molecules means lower costs of raw materials and manufacturing overall. As Jason Costigan, head of CMC for Corsera Health articulated, “We have to go where the puck is going, and I think that the puck is going toward stereopure products. I think it’s highly, highly likely that the regulatory expectation will be that you define a single diastereomer down the road,” Fleitz agreed with Costigan. “It’s not going to be next week; it’s not going to be next year. But that’s likely where we’re going.” https://www.advancingrna.com/doc/stay-stereocurious-what-the-future-holds-for-oligo-quality-0001
0 · Reply
dewmoore
dewmoore Jul. 2 at 12:02 PM
$SLS Heading into a 4-day long weekend with a Phase 3 BOMB on deck 💥 Look at Big Pharma: Pfizer paid $43B for Seagen, Gilead paid $5B for a failed AML asset + Merck faces a massive $30B patent cliff on Keytruda! They're writing $5B-$43B checks for risky assets $LLY and $JNJ sitting on massive cash piles, explicitly stating that money is no object for a de-risked asset. The last major clean oncology deal cleared $10B for ONE drug. SLS stock would be ....... $5 b Market Cap: $25.43 per share $10 b Market Cap: $50.86 per share $30 b Market Cap: $152.57 per share $43 b Market Cap: $218.68 per share $SLS isn’t just a drug; it’s a platform targeting WT1 to go after 20+ cancer killers (AML, Mesothelioma, Ovarian). Meanwhile, shorts are playing chicken with a 6-year trial where patients are surviving at unprecedented rates. The CEO just gave themselves golden parachutes.. No way in hell am I sitting on the sidelines for 4 days when news could drop Monday morning. 🚀 $LLY $JNJ $PFE $MRK
3 · Reply
Buy_SoFi
Buy_SoFi Jul. 2 at 12:00 PM
$TLTFF <----- 👀. Keep an eye on Theralase if you're in $CGON $IBRX $ENGN and looking for an undervalued cancer cure play. FDA rolling review for Ruvidar (NMIBC) about to be announced (Q3 2026), future market leader in HSV treatment and other cancer cures... These opportunities for "100x returns" don't come around very often. $MRK
0 · Reply
GordoHLYK13
GordoHLYK13 Jul. 2 at 11:53 AM
$IGC IGC is entering its biggest catalyst yet. 🚀 Phase 2 CALMA enrollment is complete, all 146 patients are locked in, and now the market is waiting for the data. The enrollment risk is gone—it’s all about the readout. IGC-AD1 targets Alzheimer’s-related agitation, a multi-billion-dollar unmet market with very few effective treatment options. If the Phase 2 results are positive, IGC could quickly move onto the radar for licensing, partnerships, or acquisition discussions. What makes this even more interesting? IGC has funded its own clinical development, giving it flexibility if the data is strong. Positive results could attract interest from biotech and pharma leaders looking to expand their neuroscience pipelines. $LLY $BIIB $MRK $PFE 👀 #Biotech #Alzheimers #Phase2 #ClinicalTrials #BigPharma #IGCPharma #Bullish
0 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 2 at 6:39 AM
$ANVS Sounds like we could be bought out by $MRK if our phase 3 Alzheimers data is good. Perhaps a bidding war from other pharma. What other companies have phase 3 Alzheimers and Parkinsons going???
2 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 2 at 3:48 AM
$ANVS ... Maria wants 20 Billion $MRK
1 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 2 at 3:47 AM
$ANVS lol- $MRK should just buy us 4 the Alzheimers data https://www.fiercebiotech.com/biotech/merck-halts-ph-2-alzheimers-trial-after-neuphoria-small-molecule-underwhelms
1 · Reply
Mike22332233
Mike22332233 Jul. 1 at 11:03 PM
$SLS UPDATED ... I said the following one month ago when SLS was $8-$9 about it going to $18-$22 after 80th event ... and people laughed ... I don't hear from them anymore !!! ... Timeline/Price Prediction: ... SLS will jump to $18-$22 after 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results 2 weeks later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a possible 5 way Bidding War -- between $MRK, $ABBV, $BMY, $PFE, and RHHBY -- the FINAL BO PRICE will be reached at $202 in Q4 of 2026 !!! ... LIKE & FOLLOW me 👉 @Mike22332233 for SLS insight you will find nowhere else
3 · Reply
Fingerlickengood
Fingerlickengood Jul. 1 at 10:24 PM
$CDXS $MRK The shorts continue to exit this scene! https://fintel.io/ss/us/cdxs
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 1 at 10:01 PM
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership $MRK $VTI $VOO $NEUP https://stocktwits.com/news/equity/markets/mrk-neup-stocks-drop-as-merck-scraps-another-alzheimers-drug-under-neuphoria-partnership/cZm3ANLR711
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jul. 1 at 6:54 PM
$MRK $NEUP
0 · Reply
Mike22332233
Mike22332233 Jul. 1 at 6:35 PM
$SLS DID YOU SEE MY STUNNING PREDICTION ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be AMAZINGLY GAME CHANGING ... We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE $ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... Like if you agree & FOLLOW ME @Mike22332233 for BO price
1 · Reply
StockRadarr
StockRadarr Jul. 1 at 6:21 PM
$MRK has terminated a Phase 2 trial for its experimental Alzheimer's drug (MK-1167), an asset partnered with Neuphoria. The decision follows a prespecified interim analysis showing the drug failed to meet efficacy criteria.
0 · Reply